mAbxience’s CEO Emmanuelle Lepine highlights the company’s international expansion into highly regulated markets, new investment into its Spanish…

In conversation at the FT’s Global Pharmaceutical & Biotechnology Conference last month, Sandoz CEO Richard Saynor outlined the current status…

The deputy director of the Spanish Biosimilar Medicines Association (BioSim), Isabel del Río, comments on the current status of biosimilars in Spain…

Formerly known as Assogenerici, Egualia is an Italian industry association representing generics and biosimilar companies. Michele Uda, its…

With an already well-established manufacturing industry for pharmaceuticals, Turkey has been aiming to move with global trends and invest in biologics…

Okan Güner of Viatris Turkey introduces the company’s sizeable footprint in the country, including local manufacturing and explains the challenges…

Arven Pharmaceuticals is the Turkish R&D-based company behind the first biosimilar drug developed and manufactured from cell to final product in…

Tore von Würden talks through Amgen Denmark’s focus areas of osteoporosis, cardiovascular disease, haematology, and oncology, where it hopes not…

Best known as the company that launched the world’s first “antibody biosimilar,” Celltrion is looking to continue its growth as a global…

Polifarma is a Turkish pharma company dedicated to the hospital sector and biosimilars. Its chairman, Ufuk Kumrulu, explains how the company has…

Süha Taşpolatoğlu, CEO of Abdi Ibrahim, Turkish pharma’s “national champion”, discusses the company’s ambitious bet on biosimilars, their…

Ilko Pharmaceuticals is a family-owned Turkish generics and biosimilars company. General Manager Hatice Öncel explains the company’s investment in…